Randomized trials neutral for pump device in complex elective cases, STEMI with reperfusio ...

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock does not significantly reduce heart damage.

In the STEMI Door-to-Unload trial, use of Impella missed the mark in patients with anterior MI without cardiogenic shock.

Seismic Pharma, a newly formed biopharmaceutical company, today announced its launch and initial financing led by Panacea Capital. The company has been formed to advance a portfolio of clinically ...

Add Yahoo as a preferred source to see more of our stories on Google. Most people who've had a heart attack—or who fear having one—focus on surviving the cardiovascular event itself. But what happens ...

Centers with multidisciplinary teams created to rapidly respond to cardiogenic shock are more likely to use invasive hemodynamic monitoring and advanced mechanical circulatory support (MCS), but less ...

Women with heart failure–related cardiogenic shock have worse outcomes and more vascular complications than men, a new analysis of registry data shows. "These data identify the need for us to continue ...

LAS VEGAS--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announces that new data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 ...

More than a quarter of patients with early-stage cardiogenic shock had to be transferred to a higher level of care, progressed to a worse stage of shock, or died, according to a study in six US ...

Please provide your email address to receive an email when new articles are posted on . “The women and men in our study had similar clinical characteristics when they developed cardiogenic shock after ...

Cardiogenic shock occurs when your heart suddenly fails to pump enough blood for your vital organs. It’s the leading cause of death in heart attack patients. New study results show using a special ...

Against expectations, critically ill people in cardiogenic shock fared similarly receiving one widely used inotrope or another in the small DOREMI trial. Patients had the same clinical outcomes on ...